Simpson Group - Research projects

The ins and outs of endocytosis inhibition: providing diverse opportunities for treatment of incurable cancers.

Therapeutic targets and immune therapy for head and neck adenoid cystic carcinoma.

Open-label Phase II study investigating the efficacy of Cetuximab and prochlorperazine (Stemetil) combination therapy in patients with metastatic Head and Neck Carcinoma (CESTEM II study).

HER2Stem: Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study.

Solving surgical and therapeutic issues in the treatment of Pancreatic ductal adenocarcinoma (PDAC).

Novel Biomarkers and Treatment Approaches in Breast Cancer.

Analysis of markers of progression and recurrence in breast cancer.

Combination therapies to improve delivery of PSMA-targeted therapies.

Novel therapeutic strategies for treatment of cutaneous SCCHN with perineural invasion.

Characterising the protein complexes responsible for immune synapse formation to allow rational drug design to modulate immunity both as increase and decrease.